Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Irritable Bowel Syndrome | Treatment Algorithms: Claims Data Analysis | IBS-Diarrhea | US | 2022

Login to access report north_east
Contact sales account_box

characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally classified into three subtypes: constipation 
predominant, diarrhea predominant, and mixed; this analysis focuses on IBS-D, the diarrhea-predominant subtype. Limited treatment options are available for 
IBS, and only a few drugs have secured FDA approval for IBS-D. Current prescribing among recently treated and newly diagnosed IBS-D patients?
 * How have Viberzi and Lotronex been integrated into the treatment algorithm, and what are their sources of business?
 * What percentage of IBS-D patients receive drug therapy within 365 days
*Markets covered:* United States
*Key companies:* AbbVie, Salix, Sebela Pharmaceuticals
*Key drugs:* Viberzi, Xifaxan, Lotronex, dicyclomine, hyoscyamine sulphate / scopolamine, SSRIs, SNRIs, tricyclic agents, diphenoxylate
characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally classified into three subtypes: constipation 
predominant, diarrhea predominant, and mixed; this analysis focuses on IBS-D, the diarrhea-predominant subtype. Limited treatment options are available for 
IBS, and only a few drugs have secured FDA approval for IBS-D. Current    prescribing among recently treated and newly diagnosed IBS-D patients?
 * How have Viberzi and Lotronex been integrated into the treatment algorithm, and what are their sources of business?
 * What percentage of IBS-D patients receive drug therapy within 365 days
*Markets covered:* United States
*Key companies:* AbbVie, Salix, Sebela Pharmaceuticals
*Key drugs:* Viberzi, Xifaxan, Lotronex, dicyclomine, hyoscyamine sulphate / scopolamine, SSRIs, SNRIs, tricyclic agents, diphenoxylate
 

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Venous Thromboembolism – Current Treatment – Treatment Algorithms: Claims Data Analysis – Venous Thromboembolism (US)
Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus, described as deep vein thrombosis (DVT) or pulmonary embolism (PE), depending on the vein affected. Anticoagulants…
north_east
Report
Asthma – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult Asthma (US)
Two types of pharmacotherapies are used in parallel to treat adult asthma: rescue drugs and maintenance therapies. Rescue drugs are inhaled therapies that treat the acute symptoms of asthma via…
north_east
Report
Attention-Deficit-Hyperactivity Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult ADHD (US)
Attention-deficit / hyperactivity disorder (ADHD), a common childhood neurodevelopmental condition that can persist into adulthood, affects about 6% of U.S. adults, or approximately 15.5 million…
north_east
Report
Cystic Fibrosis – Unmet Need – Unmet Need – Cystic Fibrosis (US EU)
Cystic fibrosis (CF) is a genetic disease associated with more than 2,000 mutations identified in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. These mutations cause aberrant…
north_east
Report
Hyperkalemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hyperkalemia (US)
Hyperkalemia is defined as a serum potassium level above 5.0 mEq/L. This report covers the management of chronic hyperkalemia through diuretic therapy, correcting metabolic acidosis when present,…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east